## Pooja Dua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6245787/publications.pdf Version: 2024-02-01



Ροοιλ Οιιλ

#	Article	IF	CITATIONS
1	Development of Single-Stranded DNA Aptamers for Specific Bisphenol A Detection. Oligonucleotides, 2011, 21, 85-91.	2.7	163
2	Dual Functions of Highly Potent Graphene Derivative–Poly- <scp>l</scp> -Lysine Composites To Inhibit Bacteria and Support Human Cells. ACS Nano, 2012, 6, 7151-7161.	7.3	141
3	Nucleic acid aptamers targeting cell-surface proteins. Methods, 2011, 54, 215-225.	1.9	95
4	Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein. Cancer Research, 2013, 73, 1934-1945.	0.4	80
5	Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 195-202.	1.1	44
6	Modified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing. Molecular Therapy, 2011, 19, 1676-1687.	3.7	37
7	Enhanced intracellular delivery and multiâ€target gene silencing triggered by tripodal RNA structures. Journal of Gene Medicine, 2012, 14, 138-146.	1.4	36
8	Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. European Journal of Cancer, 2008, 44, 1587-1595.	1.3	33
9	A Sol–Gel-Based Microfluidics System Enhances the Efficiency of RNA Aptamer Selection. Oligonucleotides, 2011, 21, 93-100.	2.7	31
10	Patents on SELEX and Therapeutic Aptamers. Recent Patents on DNA & Gene Sequences, 2008, 2, 172-186.	0.7	26
11	ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2′-Deoxyuridine to Pancreatic Cancer. Nucleic Acid Therapeutics, 2015, 25, 180-187.	2.0	26
12	Evaluation of Toxicity and Gene Expression Changes Triggered by Oxide Nanoparticles. Bulletin of the Korean Chemical Society, 2011, 32, 2051-2057.	1.0	26
13	Suramin augments the antitumor and antimetastatic activity of pentoxifylline inB16F10 melanoma. International Journal of Cancer, 2007, 121, 1600-1608.	2.3	25
14	Structural Diversity Repertoire of Gene Silencing Small Interfering RNAs. Nucleic Acid Therapeutics, 2011, 21, 125-131.	2.0	24
15	Long dsRNA-Mediated RNA Interference and Immunostimulation: A Targeted Delivery Approach Using Polyethyleneimine Based Nano-Carriers. Molecular Pharmaceutics, 2014, 11, 872-884.	2.3	22
16	Cell-SELEX Based Identification of an RNA Aptamer for Escherichia coli and Its Use in Various Detection Formats. Molecules and Cells, 2016, 39, 807-813.	1.0	22
17	Evaluation of Toxicity and Gene Expression Changes Triggered by Quantum Dots. Bulletin of the Korean Chemical Society, 2010, 31, 1555-1560.	1.0	17
18	Cell-SELEX-Based Identification of a Human and Mouse Cross-Reactive Endothelial Cell-Internalizing Aptamer. Nucleic Acid Therapeutics, 2018, 28, 262-271.	2.0	15

Pooja Dua

#	Article	IF	CITATIONS
19	Long Double-Stranded RNA-Mediated RNA Interference and Immunostimulation: Long Interfering Double-Stranded RNA as a Potent Anticancer Therapeutics. Nucleic Acid Therapeutics, 2011, 21, 149-155.	2.0	14
20	ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles. Molecular Therapy - Methods and Clinical Development, 2019, 15, 204-210.	1.8	13
21	Selection of <scp>DNA</scp> Aptamers Against Botulinum Neurotoxin E for Development of Fluorescent Aptasensor. Bulletin of the Korean Chemical Society, 2017, 38, 324-328.	1.0	5
22	L-Type Calcium Channel Blocker Enhances Cellular Delivery and Gene Silencing Potency of Cell-Penetrating Asymmetric siRNAs. Molecular Pharmaceutics, 2020, 17, 777-786.	2.3	4
23	Cell-based aptamer selection for diagnosing cancer and predicting cancer progression. Toxicology and Environmental Health Sciences, 2009, 1, 140-143.	1.1	3
24	The Design, Preparation, and Evaluation of Asymmetric Small Interfering RNA for Specific Gene Silencing in Mammalian Cells. Methods in Molecular Biology, 2013, 942, 135-152.	0.4	3
25	Retinoic Acid-Inducible Gene I-Mediated Innate Immune Stimulation by Chemically Synthesized Long Double-Stranded RNAs Is Structure and Sequence Dependent. Nucleic Acid Therapeutics, 2022,	2.0	0